It has been demonstrated that the expression of biomarkers such as KRAS, NRAS, and BRAF, in conjunction with the MSI state of the tumour, serves as a negative predictor for anti-EGFR therapy in mCRC patients [11,26]. This evidence concerns the gene BRAF and neoplasm.